Santalis Pharmaceuticals Inc., of San Antonio, said it enrolled the first U.S. subject in a phase II, placebo-controlled, double-blind, safety, tolerability and efficacy study of a 5 percent sandalwood album oil, also known as East Indian sandalwood oil, cream formulation for the treatment of atopic dermatitis. Subjects will be 18 to 65 years old with a clinically stable diagnosis of atopic dermatitis with a total body surface area involvement of 2 percent to 15 percent. Up to 60 subjects will be enrolled to determine preliminary efficacy after 28 days of twice-a-day treatment.